Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Investigational MenC-CRM + LHD153R
- Development stage
- Preclinical
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Investigational MenC-CRM + LHD153R is a combination vaccine candidate under investigation. "MenC-CRM" refers to a meningococcal group C conjugate vaccine in which the capsular polysaccharide from *Neisseria meningitidis* serogroup C is conjugated to the CRM197 protein, a non-toxic mutant of diphtheria toxin commonly used as a carrier protein in conjugate vaccines[6]. Such vaccines induce T-cell dependent immune responses and are designed to protect against invasive disease caused by *Neisseria meningitidis* group C. The addition of "LHD153R" suggests inclusion of another component or adjuvant, but there is no publicly available information on "LHD153R" as an established vaccine component or adjuvant. The combination is likely being developed for enhanced immunogenicity against meningococcal disease (serogroup C), possibly with novel adjuvantation or delivery technology.
- Other names
- MenC-CRMLHD153RLHD-153RLHD 153R
02
Targets
TLR7 (Toll-like receptor 7)BCR (Immunoglobulin G B Cell Receptor)Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on Investigational MenC-CRM + LHD153R.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Investigational MenC-CRM + LHD153R.